Form 4: Sage Therapeutics Executive Gregory L. Shiferman Reports Stock Transactions Following PSU Vesting
SEC Form 4 Filing
Gregory L. Shiferman, a Senior Vice President at Sage Therapeutics, reports the acquisition and disposal of common stock following the vesting of Performance Restricted Stock Units.
Summary
- On April 10, 2025, Gregory L. Shiferman, a Senior Vice President at Sage Therapeutics, acquired 525 shares of common stock upon the vesting of Performance Restricted Stock Units (PSUs).
- These PSUs were granted on February 11, 2022, and vested upon the achievement of certain milestones.
- Following the acquisition, 176 shares were disposed of to cover tax obligations at a price of $6.91 per share.
- After these transactions, Shiferman beneficially owns 31,029 shares of Sage Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Key Dates
| Date | Description |
|---|---|
| 2022-02-11 | Date Performance Restricted Stock Units (PSUs) were granted. |
| 2024-11-01 | Date of Power of Attorney authorization. |
| 2025-04-10 | Date of stock acquisition and disposal due to PSU vesting. |
| 2025-04-11 | Date of signature for the report. |
Keywords
Form 4, Sage Therapeutics, Shiferman, Stock, PSU, Vesting, Beneficial Ownership, Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.